Background: IDO1 (indolamine 2,3-dioxygenase) catalyzes the conversion of the essential amino acid tryptophan to N-formylkynurenine.  IDO1 is expressed by suppressive macrophages and in some tumor cells. IDO1 is induced by interferon gamma. The reduction of tryptophan in the tumor microenvironment and the production of kynurenine inhibit T cell responses and contribute to a suppressed immune state. Inhibition of IDO1 is an area of active research in cancer immunotherapy, particularly in combination with other therapies.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views.

Recommended Usage:Human FFPE: 3 ug/mL dilution. For optimal results, the antibody should be titrated for each desired application.

References

• Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K.L,, Wu, M., Wainwright, D.A. IDO1 in cancer: a Gemini of immune checkpoints. Cellular & Molecular Immunology. 2018; 15:447–457.

* Conjugate tested on human tissue.